Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products

Inclusion Criteria: * Male patients with a diagnosis of haemophilia A * Received prophylactic treatment with a factor product for management of haemophilia A in the 12 months prior to enrolment * At enrolment prescribed prophylactic treatment with Elocta or conventional factor product regardless of participation in the study * Having at least 12 months documented pre-study treatment data regarding prophylactic treatment prescriptions and bleeding episodes prior to the baseline visit * Signed and dated informed consent provided by the patient or the patient's legally acceptable representative for patients under the legal age before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations Exclusion Criteria: * Enrolment in a concurrent clinical interventional study involving intake of an investigational medicinal product (IMP), within 1 year prior to enrolment * Previously treated with commercially available extended half-life products other than Elocta * Presence of factor VIII inhibitors (≥0.60 Bethesda Unit \[BU\]/mL ) at the latest available inhibitor test using the Nijmegen modified Bethesda assay